Boosted coupling of ATP hydrolysis to substrate transport upon cooperative estradiol-17-beta-D-glucuronide binding in a Drosophila ATP binding cassette type-C transporter by Karasik, A. et al.
	 1	
Title: 1 
 2 
Boosted coupling of ATP hydrolysis to substrate transport upon cooperative estradiol-17-ß-D-3 
glucuronide binding in a Drosophila ABCC transporter 4 
 5 
Short title: 6 
Increased coupling by cooperative substrate binding in Drosophila ABCC 7 
 8 
Authors: 9 
Agnes Karasik1, Kaitlyn Victoria Ledwitch2, Tamás Arányi1, András Váradi1, Arthur Roberts2, Flóra 10 
Szeri1# 11 
 12 
1Institute of Enzymology, Research Centre for Natural Sciences - Hungarian Academy of Sciences, 13 
Budapest, Hungary 14 
2Department of Pharmaceutical and Biomedical Sciences, University of Georgia, Athens, USA 15 
 16 
#Corresponding author, email address: szeri.flora@ttk.mta.hu 17 
Correspondig author: 18 
Flóra Szeri 19 
Active Transport Proteins Research Group 20 
Institute of Enzymology 21 
Research Centre for Natural Sciences 22 
Hungarian Academy of Sciences 23 
Street address: Magyar tudósok körútja 2, H-1117, Budapest, Hungary 24 
Postal address: 1519 Budapest, Pf. 286, Hungary 25 
Phone: +36 306703955 26 
Fax: 3613826700 27 
 28 
Current affiliation: Department of Dermatology and Cutaneous Biology, 29 
Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, 30 
PA, USA 31 
 32 
 33 
Funding sources: 34 
 35 
This work was supported by the Hungarian Országos Tudományos Kutatási Alapprogramok (OTKA) (Grants 36 
104227 and 114336), Grant VKSz14-1-2015-0155 from theHungarian National Research, Development, and 37 
Innovation Office, a grant from the Fulbright Research Scholar by the J. William Fulbright Foreign Scholarship 38 
Board, and U.S. National Institutes of Health, National Cancer Institute Grant R01-CA204846-01A1. The authors 39 
declare no conflicts of interest. 40 
  41 
	 2	
List of nonstandard abbreviations: 1 
 2 
ABC = ATP Binding Cassette 3 
ABCC = ATP-Binding Cassette type-C 4 
ATP = adenosine triphosphate 5 
CDCF = 5-(and-6)-carboxy-2',7'-dichlorofluorescein 6 
COPASI = COmplex PAthway SImulator 7 
DKM = Double KM Mutant 8 
DMRP = Drosophila MRP  9 
DMSO = dimethyl sulfoxide 10 
E217βD = estradiol-17-ß-D-glucuronide 11 
E2G (in figures) = estradiol-17-ß-D-glucuronide 12 
EGTA = ethylene glycol-bis (2-aminoethylether)-N,N,N′,N′-tetraacetic acid 13 
Kd = dissociation constant 14 
KM = Michaelis-Menten contstant 15 
MOPS = 3-(N-Morpholino) propanesulfonic acid 16 
MRP = Multidrug Resistance-associated Protein 17 
NBD = nucleotide binding domain 18 
Pi = inorganic phosphate 19 
SDS = sodium dodecyl sulfate 20 
Sf9 = Spodoptera frugiperda 21 
Tmax = maximum transport rate 22 
TMD = transmembrane domain 23 
TRIS = 2-amino-2-(hydroxymethyl)-1,3-propanediol 24 
vbasal = basal ATP hydrolysis rate 25 
Vmax = maximum rate of ATP hydrolysis  26 
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Abstract 1 
 2 
ABCC (ATP-Binding Cassette type-C) transporters move molecules across cell membranes upon hydrolysis of 3 
ATP, however their coupling of ATP hydrolysis to substrate transport remains elusive. Drosophila MRP 4 
(DMRP) is the functional ortholog of human long ABCC transporters, with similar substrate and inhibitor 5 
specificity but higher activity. Exploiting its high activity, we kinetically dissected the catalytic mechanism of 6 
DMRP using estradiol-17-ß-D-glucuronide (E217βD), the physiological substrate of human ABCCs. We 7 
examined DMRP-mediated interdependence of ATP and E217βD in biochemical assays. We found E217βD 8 
dependent ATPase activity to be biphasic at subsaturating ATP concentrations implying at least two E217βD 9 
binding sites on DMRP. Furthermore, transport measurements indicated strong non-reciprocal cooperativity 10 
between ATP and E217βD. Besides confirming these findings, our kinetic modelling with COmplex PAthway 11 
SImulator (COPASI) indicated a ten-fold drop in E217βD mediated activation of ATP hydrolysis upon 12 
saturation of the second E217βD binding site. Surprisingly, the binding of the second E217βD allowed substrate 13 
transport with constant rate, tightly coupling ATP hydrolysis to transport. In conclusion, we show that the 14 
second E217βD binding, similarly to human ABCC2, allosterically stimulate transport activity of DMRP. Our 15 
data suggest that this is achieved by significant increase of coupling of ATP hydrolysis to transport. 16 
 17 
Keywords:  18 
 19 
Multidrug Resistance-associated Protein (MRP), vanadate-sensitive ATPase activity, E217βD transport, kinetic 20 
modelling, COmplex PAthway SImulator (COPASI), allosteric cooperativity 21 
 22 
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1. Introduction		1 
ABC (ATP Binding Cassette) proteins are present in all kingdoms of life (1). Most eukaryotic ABC proteins are 2 
involved in efflux of endo- and xenobiotics across biological membranes utilizing the energy of ATP 3 
hydrolysis. The minimal functional unit of ABC transporters is composed of two membrane-spanning 4 
transmembrane domains (TMDs) that form binding sites and a translocation pathway for substrates and two 5 
cytoplasmic nucleotide binding domains (NBDs) that bind and hydrolyse ATP (2). In the NBDs two molecules 6 
of ATP are sandwiched between highly conserved motifs (3), such as Walker A and B of one NBD, and 7 
signature motif of the opposing NBD forming two composite catalytic sites in head-to-tail orientation (4-6). 8 
NBDs are connected to the TMDs by cytoplasmic loops. It is generally accepted that in the mechanism of ABC 9 
transporters ATP binding and hydrolysis is coupled to substrate transport (7). Nucleotide binding and hydrolysis 10 
at catalytic centres drive conformational changes of the TMDs resulting in the alternated exposure of the 11 
substrate-binding site on each side of the membrane (8) enabling unidirectional solute transport (3, 9). Certain 12 
ABC transporters may exhibit uncoupled futile ATP hydrolysis cycles without transport of the substrates or 13 
show loose coupling of ATP hydrolysis to solute transport (10-12). The coupling mechanism of ABC 14 
transporters is largely unknown. 15 
Members of the C-subfamily of ABC proteins, ABCC transporters, harbour a pair of non-equivalent asymmetric 16 
catalytic centres (13-16). The N-terminal catalytic centre is degenerate, in which conserved residues deviate 17 
from the generally accepted consensus sequences. The C-terminal catalytic centre agrees with the consensus 18 
sequence of ABC transporters. In ABCC transporters there is a unique interdependent asymmetric positive 19 
allosteric interaction of the two NBDs, with ATP hydrolysis occurring predominantly at the consensus site, 20 
facilitated by ATP binding at the degenerate site (17-20). It has recently been shown that the degenerate site 21 
allosterically stabilizes the NBD dimer by preventing its full separation during the transport cycle (20, 21), 22 
which is the hallmark of the unique mechanism ABCC transporters (21-26). Despite of the physiological and 23 
pathological relevance of ABCC transporters, details of their molecular mechanism remain to be elucidated. 24 
In a subset of ABCC proteins, the so-called long ABCC proteins, in addition to the general core structure of two 25 
TMDs and two NBDs, there is an additional trans-membrane domain (TMD0) N-teminally linked to the core by 26 
an intracellular loop (L0) (24, 27). Long human ABCC transporters (ABCC1, 2, 3, 6 and 10) have key role in 27 
the compartmentalization of biologically active endogenous/exogenous compounds, such as inflammatory 28 
mediators, hormone derivatives, conjugated bile salts and drug metabolites (28). Furthermore, some are 29 
considered to play a role in multidrug resistance in cancer chemotherapy (28, 29). In addition, loss of ABCC2 30 
leads to Dubin-Johnson syndrome characterized by hyperbilirubinemia (30, 31), while mutations of ABCC6 are 31 
found in patients with Pseudoxanthoma elasticum (PXE) manifesting soft tissue calcification (32, 33). 32 
Estradiol-17-ß-D-glucuronide (E217βDG) is a substrate of all but one human long ABCC transporters (ABCC1-33 
3 and 10) (34-38). E217βDG is the major toxic intermediate of the human estrogene metabolism. Under 34 
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physiological conditions it is secreted into the bile mainly via ABCC2 (39, 40). In hepatotoxic conditions the 1 
level of E217βDG might be increased, inducing the expression of the sinusoidal ABCC3 (41-43). ABCC3 2 
eliminates toxic compounds, such as E217βDG, from the hepatocytes into blood thus compensate for the 3 
impaired hepatobiliary efflux (44, 45). It has been suggested recently that ABCC2 harbours two E217βDG 4 
binding sites (44, 46). E217βDG binding to the second allosteric site through positive cooperativity activates the 5 
transport of the first bound E217βDG molecule, or that of another ABCC2 substrate. (44, 46). However, the 6 
exact mechanism of this allosteric activation remains to be elucidated. 7 
DMRP is the sole ortholog of long human ABCCs in Drosophila melanogaster with high sequence identity and 8 
similarity (47-50). DMRP has similar substrate (E217βDG, leukotriene C4, 5-(and-6)-Carboxy-2',7'-9 
dichlorofluorescein (CDCF), calcein and fluo3) and inhibitor (probenecid, benzbromarone, indometacin and 10 
MK571) specificity to long human ABCC transporters (48). Additionally, reduced expression of endogenous 11 
DMRP correlates with decreased secretion of the ABCC1 substrate daunorubicin in Malpighian tubules (51). 12 
DMRP in addition plays a role in protection against mercury during fly development (52), which is consistent 13 
with inorganic mercury being a substrate of ABCC2 in mice (53).  In addition to the shared substrate and 14 
inhibitor profile, DMRP exhibits elevated activity in in vitro biochemical assays. In the absence of substrates 15 
the so called “basal” ATPase activity of human ABCC transporters is low (54) making investigations arduous or 16 
impossible. In contrast, DMRP exhibits approximately 15 times higher basal ATPase activity, expressed in the 17 
same system (48). DMRP also accomplishes high transport rates. It has one order of magnitude higher activity 18 
for E217βDG, leukotriene C4 and fluo3 and significantly elevated transport rate for CDCF in comparison to 19 
human ABCCs (48, 54). DMRP can be thus considered as a faithful model of human long ABCC transporters, 20 
suitable to gain mechanistic insight into processes difficult to study in the human ABCCs.  21 
In the present study we investigated DMRP mediated coupling between ATP hydrolysis and E217βDG 22 
transport. By functional assays and molecular modelling we showed that substrate binding to a second allosteric 23 
site highly increases coupling efficiency of these otherwise loosely coupled mechanisms. 24 
 25 
2. Materials	and	methods	26 
2.1. Materials	27 
Restriction endonucleases and T4 ligase were obtained from Thermo Fisher Scientific (Waltham, MA, USA) 28 
and New England Biolabs (Ipswich, MA, USA), Pfu polymerase was provided by Strategene (Jolla, CA, 29 
USA). Oligonucleotides were ordered from Metabion International AG (Planegg, Germany) and Biological 30 
Research Centre of Szeged (Szeged, Hungary). [3H] estradiol-17-ß-D-glucuronide ([3H] E217ßG; 48 31 
Ci/mmol) was purchased from PerkinElmer Life Sciences (Waltham, MA, USA). The anti-DMRP 32 
polyclonal antiserum pAB7655, was raised against a synthetic peptide corresponding to amino acids 209-222 33 
of DMRP and was obtained from ZYMED Laboratories Inc. (South San Francisco, CA, USA) as described 34 
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previously (47). Secondary HRP-conjugated anti-rabbit antibodies were purchased from Jackson 1 
ImmunoResearch (West Grove, PA, USA). Nitrocellulose membrane filters (HWAP00250) were obtained 2 
from Millipore (Billerica, MA, United States), and scintillation fluid (Opti-fluor) from PerkinElmer 3 
(Waltham, MA, USA). ECL was obtained from Amersham Biosciences (Piscataway, NJ, USA). All other 4 
compounds were obtained from Sigma Aldrich (St. Louis, MO, USA). E217βDG was dissolved in DMSO, 5 
the final concentration of DMSO in the assay buffer was kept less than 0.1% in transport and less than 1% in 6 
ATPase experiments. 7 
 8 
2.2. Methods	9 
2.2.1. Generation	of	constructs	10 
The mutations in the Walker A motifs were generated by Quickchange site-directed mutagenesis. The 8a 4b 11 
isoform of dMRP cDNA (SD07655) was cloned into pAcUW21L (modified pAcUW vector by Szakács et al.) 12 
previously (47). Using this construct, we isolated two DNA fragments containing the sequences of the N- and 13 
C- terminal Walker A motifs of dMRP by EcoRI-EcoRV and EcoRV and SacI restriction endonucleases. These 14 
fragments were cloned into pBluescript KS- vectors, which were used as templates for the PCR mutagenesis 15 
reactions. Sequences of the partially overlapping upper and lower primers carrying the mutations of K687M and 16 
K1349M were the following:  17 
5’-CGGTTCCGGCATGTCGTCTGTAGTGCAGGCATTCC-3’,  18 
5’-CTACAGACGACATGCCGGAACCGACCGTGCCAACC-3’,  19 
5’-GGTGCCGGCATGTCCAGTCTCACATTGGCCTTGTTCAG-3’, 20 
5’GTGAGACTGGACATGCCGGCACCAGTGCGACCAACAATGC-3’, 21 
respectively. Fragments containing the desired mutations were cloned back into dMRP cDNA in pAcUW21L 22 
vector with T4 ligase and restriction endonucleases mentioned above, generating double and single Walker A 23 
lysine mutant dMRP constructs. The presence of the mutation and the fidelity of the sequence of coding region 24 
of dMRP were confirmed by dideoxy sequencing. 25 
 26 
2.2.2. Expression	in	Sf9	cells,	membrane	preparation	and	immunoblotting	27 
Recombinant baculovirus particles containing the dMRP cDNA (SD07655) were prepared as described 28 
previously (47). Sf9 cells were cultured and infected with the recombinant baculovirus. After 3-days of virus 29 
infection the Sf9 cells were harvested, the membranes were isolated and stored at -70˚C as described previously 30 
(55). Total membrane protein concentrations were determined by the modified Lowry method (56). Gel 31 
electrophoresis and immunoblotting were performed as described previously (47). Briefly, membrane 32 
preparations of Sf9 cells overexpressing wild type or Walker A lysine mutant DMRPs or β-galactosidase (β-gal) 33 
containing 5 µg total membrane protein were run on 7.5 % SDS-PAGE gel. Proteins were electro-blotted and 34 
	 7	
detected by chemo-luminescence using the anti-DMRP polyclonal antiserum pAB7655 (1:500) and HRP 1 
conjugated anti-rabbit antibody (1:10000). 2 
 3 
2.2.3. Vesicular	transport	measurements	4 
Vesicular transport measurements with radio-labelled substrates were performed using a rapid filtration method 5 
(47). Critical parameters such as incubation time, temperature and the amount of Sf9 vesicles used were 6 
determined previously. Parameters that best estimated initial velocities were used in the experiments. Briefly, 7 
isolated inside-out Sf9 membrane vesicles containing 100 µg total membrane protein, were incubated at 37 ˚C 8 
for 0.5 minutes in the absence or presence of Mg2+ATP of indicated concentration in 150 µl of transport buffer 9 
(6 mM MgCl2, 40 mM MOPS-Tris, pH 7.0, 40 mM KCl) at 37°C. Incubation was stopped by the administration 10 
of 800 µl of ice-cold washing buffer (40 mM MOPS-TRIS, pH 7.0, 70 mM KCl), after 0.5 min, and samples 11 
were instantly filtered through the 0.45 µm pore size nitrocellulose membrane filters (Millipore). Filters were 12 
washed twice with 5 ml cold washing buffer and the filter-bound radioactivity was measured in scintillation 13 
fluid (Opti-fluor, PerkinElmer) using Wallac 1409 DSA scintillation counter. ATP-dependent transport was 14 
calculated by subtracting the values obtained in the absence from those in the presence of ATP.  15 
 16 
2.2.4. ATPase	activity	measurements	17 
The vanadate-sensitive ATPase activity was measured by colorimetric detection of inorganic phosphate 18 
liberation as described previously (47, 48, 55). Critical parameters such as incubation time, temperature and the 19 
amount of Sf9 vesicles used were determined previously. Conditions that best estimated initial velocities were 20 
used in the experiments. In brief, membrane suspensions containing 30 µg (wild type DMRP), 50 µg (K687M) 21 
or 100 µg (K1349M, DKM) of total membrane protein were incubated at 37˚C for 5 minutes in 150 µl of a 22 
medium containing 40 mM MOPS-Tris, pH 7.0, 0.5 mM EGTA-TRIS, 2 mM dithiothreitol, 50 mM KCl, 5 mM 23 
sodium azide, and 1 mM ouabain. The ATPase reaction was started by the addition of Mg2+ATP at indicated 24 
concentrations. The reactions were stopped by the addition of 0.1 ml of 5% SDS, and the amounts of inorganic 25 
phosphate were determined based on a colorimetric reaction. The optical density was read at 700 nm after 15 26 
min incubation. ATPase activity was calculated as the difference obtained in Pi levels between 0-min reaction 27 
(stopped immediately with SDS) and reactions after the indicated incubation periods. Vanadate-sensitive 28 
ATPase activities were calculated as the difference between values measured in the presence and in the absence 29 
of 1.33 mM vanadate.  30 
 31 
2.2.5. Calculation	of	kinetic	parameters	of	ATPase	and	vesicular	transport	measurements	32 
Data were fitted by Michaelis-Menten equation using Igor Pro 6.2 (57-59). Monophasic ATP hydrolysis 33 
kinetics was fit to a modified Michaelis Menten Equation (57-59): 34 
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𝑣 = #$%&	[)]+,-[)] + 𝑣/0102	  (1) 1 
where v is the ATP hydrolysis rate, Vmax is the maximum ATP hydrolysis rate, vbasal is the basal ATP hydrolysis 2 
rate, KM is the Michaelis-Menten contstant and L is the transported substrate. Biphasic ATP hydrolysis kinetics 3 
was fit to modified substrate inhibition equation (Equation 2) (57-59): 4 𝑣 = #$%&		3-4,5 -	 546 + 𝑣/0102 (2) 5 
where KI is the inhibitory constant. Monophasic transport kinetics was fit another variation of the Michaelis-6 
Menten Equation (57, 58):  7 𝑡 = 8$%&	[)]+,-[)] 	   (3)      8 
where to t is the apparent transport rate and Tmax is the maximum transport rate. 9 
 10 
2.2.6. Kinetic	modelling	11 
Transport by ABCC transporters is complex and involves the substrate binding, ATP hydrolysis and transport. 12 
Specialized fitting equations can work in some of these complex cases, but often require numerical methods that 13 
result in multiple solutions e.g. (60). As a result, a variety of advanced software modelling packages have been 14 
developed to fit arbitrary kinetic models including the free Complex Pathway Simulator (COPASI) (61) and the 15 
proprietary Berkeley Madonna (University of California, Berkeley, CA). To estimate the discrete microscopic 16 
kinetic parameters such as Vmaxs and Kds the transport and DMRP-mediated ATP hydrolysis in this study were 17 
fit to kinetic models using the evolutionary algorithm in the COPASI software as described (59, 61, 62). The 18 
software can fit both kinetic and steady state curves with indeterminate number of independent fitting 19 
parameters (61). 20 
 21 
3. Results	22 
3.1. Catalytic	sites	of	DMRP	are	functionally	non-equivalent.	23 
The conserved Walker A lysine contributes to ATP binding (63) promoting dimerization of the NBDs. Mutation 24 
of the N and C-terminal Walker A lysines to methionine alter activity of human ABCC1 differently (13) 25 
revealing the functional non-equivalency of the catalytic sites of ABCC proteins. In order to test the functional 26 
equality of DMRP we investigated the consequences of single N- or C -terminal or double mutations of the 27 
conservative Walker A lysines to methionines, K687M, K1349M and K687M/K1349M referred to as DKM 28 
(Double KM Mutant), respectively. The mutant and wild type proteins were overexpressed in Spodoptera 29 
frugiperda (Sf9) insect cells at comparable levels (Figure 1A) then characterized in functional assays.  30 
The vanadate-sensitive ATPase activities (later referred to as ATPase activity) of K687M, K1349M and DKM 31 
proteins were 15%, 3% and 0.8 % of the wild type DMRP, respectively (Figure 1B). In Sf9 membranes 32 
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overexpressing the wild type DMRP the vanadate-sensitive ATPase activity was 50% of the total ATPase 1 
activity measured in the absence of vanadate. DMRP is known to transport E217βDG (48). Relative E217βDG 2 
transport rates of the K687M, K1349M and DKM proteins were 48.9%, 13% and 3.7 % of the wild type protein, 3 
respectively (Figure 1C). The N-terminal Walker A lysine mutant showed significantly higher activity 4 
compared to the C-terminal Walker A mutant while the double Walker A mutant was inactive in functional 5 
assays, since E217βDG uptake in the latter vesicles did not differ significantly from Sf9 vesicles without DMRP 6 
expression. These findings support the functional disparity of the two catalytic sites of DMRP and the 7 
hypothesis that DMRP shares the same general mechanism of action as its human counterparts (13). 8 
 9 
3.2. Non-competitive	interaction	by	E217βDG	on	ATP	hydrolysis	depends	on	substrate	10 
saturation	of	two	putative	E217βDG	binding	sites	11 
In order to elucidate kinetic characteristics of the wild type DMRP, we investigated the ATPase cycle of DMRP 12 
in the absence and presence of E217βDG. First, we examined the concentration dependence of ATP and 13 
E217βDG on the DMRP-mediated ATP hydrolysis. Figure 2A shows the hyperbolic ATP hydrolysis rate as a 14 
function of ATP concentration. This curve was fit to a modified Michaelis-Menten equation 1. We extracted 15 
Vmax and KM values from this fitting of 86 +/- 4 nmol Pi/mg membrane protein/min and 0.815 +/- 0.191 mM, 16 
respectively. Next, we investigated the effect of ATP on E217βDG affinity to DMRP (Figure 2B). At saturating 17 
3.33mM ATP concentration, the curve depicting ATPase activity in function of E217βDG concentration was 18 
monophasic, which was in line with our previously published data (48). Fitting the curve to modified Michaelis-19 
Menten equation (Equation 1) gave a KI (since the ATP hydrolysis is inhibited) and the Vmax basal values of 20 
537+/-336 µM and 67.8+/-2.3 nmol Pi/mg/min, respectively. Interestingly, at subsaturating 0.5 mM ATP 21 
concentration, the curve became biphasic, implying binding of at least two molecules of E217βDG per DMRP 22 
monomer. This curve was fit to the substrate inhibition equation (Equation 2). The KM, Vmax and the KI from the 23 
fit were 62 +/- 31 µM, 100 +/- 364 nmol Pi/mg/min, and 30.4 +/- 146 µM, respectively. The ATPase activity 24 
measured in the presence of the loss of function DKM DMRP was negligible and unaltered by E217βDG (data 25 
not shown). 26 
To get a better handle on E217βDG and ATP interaction with DMRP, the DMRP-mediated ATP hydrolysis was 27 
measured with a range of E217βDG and in function of ATP concentration (Figure 2C). The apparent DMRP-28 
mediated ATP hydrolysis was monophasic under all conditions, so it was fit to the modified Michaelis-Menten 29 
equation (Equation 1). The fitted KMs and Vmaxs are shown in Figure 2D on the left and right Y axis for KM and 30 
Vmax, respectively.  The KM of ATP decreases from 815 +/- 190 µM to 198 +/- 23 µM with increasing 31 
concentrations of E217βDG. This result implies that there is positive cooperativity between E217βDG and ATP. 32 
The Vmax also decreases from a maximum of 80.79+/-1.25 nmol Pi/mg/min to 25.11+/-0.83 Pi/mg/min.  33 
 34 
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3.3. Non-reciprocal	positive	cooperativity	of	E217βDG	toward	ATP	in	the	transport	cycle	of	1 
DMRP	2 
ATPase activity in principle is directly linked to transport of substrates in the working mechanism of ABC 3 
transporters. Therefore, we investigated whether the putative positive cooperativity detected as an E217βDG 4 
concentration dependent shift of the affinity for ATP found in ATPase activity is characteristic to E217βDG 5 
transport.  6 
First, we determined the E217βDG transport rate as the function of ATP concentration (Figure 3A) at 10 and 7 
100 µM E217βDG concentration. We extracted transport kinetic parameters from the monophasic curves fitted 8 
to the modified Michaelis-Menten equation (Equation 3). We found that at 100 µM E217βDG concentration the 9 
KM value for ATP was decreased by a factor of 2.4 relative to the lower E217βDG concentration (Figure 3B) 10 
(697 +/- 93 µM and 293 +/- 38 µM ATP, respectively). This again implied positive cooperativity of E217βDG 11 
towards ATP and reinforced our findings in ATPase activity measurements. Interestingly, though we detected 12 
an inhibitory effect of E217βDG on the rate of ATP hydrolysis, in transport at the higher E217βDG 13 
concentration Tmax (maximal transport rate) value was increased by a factor of 2.5 relative to the lower 14 
E217βDG concentration (Figure 3B) (470+/-26 to 1198 +/-49 nmol E217βDG /mg/min for 10 and 100 µM 15 
E217βDG, respectively).  16 
Next, we were interested in the reciprocity of the positive cooperativity of E217βDG and ATP in transport 17 
experiments. Figure 3C shows E217βDG transport by DMRP in the function of E217βDG concentration at 18 
distinct ATP concentrations. Fitting of the monophasic curves to the modified Michaelis-Menten equation 19 
(Equation 3) yielded omissible changes of KM (48.92+/- 11.7, 46.8 +/- 5.5 and 66.4 +/- 2.5 µM E217βDG for 20 
0.25, 0.75 and 3.33mM ATP, respectively). Thus, our experiments revealed lack of reciprocity of the positive 21 
cooperativity of E217βDG and ATP in transport measurements. However, increasing concentration of ATP 22 
elevated the initial transport rate of E217βDG with a factor of 3.4 (Tmax values were 1362+/-112, 3014+/-121 23 
and 4649+/-65 nmol E217βDG /mg/min for 0.25, 0.75 and 3.33mM ATP, respectively) (Figure 3D).  24 
 25 
3.4. Kinetic	modelling	of	the	mechanism	of	DMRP		26 
Our experiments hinted at two potential binding sites for E217βDG and suggested a unidirectional positive 27 
cooperativity for E217βDG and ATP. The determined global values for the apparent kinetic parameters of ATP 28 
hydrolysis and E217βDG transport did not provide enough detail to resolve the complex catalytic mechanism of 29 
DMRP. Therefore, to further dissect the kinetics of DMRP by using the software COPASI we built a kinetic 30 
model with two E217βDG binding sites (Figure 4). Consequent to the two E217βDG binding sites in our model 31 
there are also states for ATP binding in the absence and presence of one or two E217βDG molecules bound to 32 
the transporter. The ATP hydrolysis and transport in the presence of a single and double molecules of E217βDG 33 
are shown on the top of the Figure 4.  To obtain the microscopic kinetic parameters such as Vmaxs and Kds, the 34 
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experimentally determined data were fit with COPASI, as described previously (59, 62), using the kinetic model 1 
in Figure 4. 2 
 3 
3.5. Both	E217βDG	binding	sites	are	cooperative	with	ATP	binding	4 
Our in vitro experiments hinted that there are at least two binding sites for E217βDG in DMRP. We also found 5 
that the apparent KM of ATP decreased in the presence of E217βDG implying positive cooperativity with respect 6 
to substrate binding (Figure 2D). Since our experiments indicated that there are two molecules of E217βDG 7 
binding to DMRP with putative positive cooperativity, first we fit curves without biasing toward non-8 
cooperative or cooperative models.  In case of supposing cooperativity per se we did not know if singly or 9 
doubly E217βDG occupied DMRP is cooperative with ATP. Therefore, we fitted the curves in Figure 2B in 10 
Figure 5 to different models for cooperativity. We defined the individual E217βDG binding sites as "site #1" 11 
and "site #2". In Figure 5A, the experimentally determined data points of Figure 2B at 0.5 mM ATP were fit 12 
assuming four different models: 1) Both bound E217βDG molecules are cooperative with bound ATP, 2) 13 
E217βDG bound at "site #1" is cooperative with ATP, 3) E217βDG bound at "site #2" is cooperative with bound 14 
ATP and 4) E217βDG and ATP are not cooperative. In our calculations, the Kd for ATP was fixed at 815 µM 15 
based on the value derived from our in vitro experiments (Figure 2A). The values extracted from analysis with 16 
COPASI are shown in Table 1. The fits to model #1 and model #2 at subsaturating 0.5 mM ATP concentration 17 
gave R-correlation values greater than 0.92, while models #3 and #4 were poor fits. Figure 5B shows the fits of 18 
models #1 and #2 to data from Figure 2B at 3.3 mM ATP. Model #1 had an R-correlation of 0.996 and a Chi2 of 19 
0.31. In contrast, the fit to model #2 had a relatively good R-correlation of 0.971, but the Chi2 was more than 20 
30-fold higher at 10.35. Therefore, assuming, that the transporter does not switch mechanism upon ATP 21 
saturation, model #1, where both E217βDGs are cooperative, is the most likely interaction of E217βDG and 22 
ATP. Based on best fitting further on we used model #1 for the simulations. 23 
 24 
3.6. Saturation	of	second	E217βDG	site	results	in	significant	drop	of	ATP	hydrolysis	rate	25 
We have determined fits by COPASI for DMRP-mediated ATP hydrolysis (Table 2) The Kd of ATP (i.e. Kd1) in 26 
the absence of E217βDG was fixed at 815 µM according to our data (Figure 2A). Since we found that both 27 
bound E217βDGs are cooperative with ATP, Kd2 was made to be equal to Kd3, and Kd4 was made to be equal to 28 
Kd5. The average R-correlation and Chi2 values of the fits derived from data referring to ATP hydrolysis were 29 
0.995 and 0.764, respectively, showing that the experimental data correlates well with the model (Table 2). The 30 
fitted basal Vmax (i.e. Vmax basal) was 78 +/- 10 nmol/mg/min, which is close to the fit with equation #1 in Figure 31 
2A of 86 +/- 4 nmol/mg/min and is in line with our previous results (48). In the presence of one bound molecule 32 
of E217βDG, the average Vmax (i.e. Vmax1) of DMRP-mediated ATP hydrolysis remained constant at 79 +/- 8 33 
	 12	
nmol/mg/min. With two bound molecules of E217βDG, the Vmax (i.e. Vmax2) declined by almost 90 % to 9 +/- 1 1 
nmol/mg/min. 2 
 3 
3.7. Coupling	of	ATPase	to	transport	is	suggested	to	be	highly	increased	upon	saturation	of	the	4 
second	E217βDG	binding	site	5 
ATP hydrolysis kinetics of DMRP was successfully simulated according to model #1. Therefore model #1 was 6 
used to obtain transport data in Figures 3A and 3C. The Kd for ATP in the absence of E217βDG was assumed to 7 
be 815 µM. In all cases, the R-correlation was >0.973 and the Chi2 was less than 0.015 showing good fits. Fits 8 
to the normalized transport rates gave Vmax values of 0.58 and 0.61 nmol E217βDG/mg membrane protein/min, 9 
which reflected relative transport rates with singly and doubly E217βDG bound DMRP, respectively. Curiously, 10 
the transport rates remained constant with E217βDG, despite of an almost 10-fold decrease in DMRP-mediated 11 
ATP hydrolysis. In order to keep the relative transport rate constant under these conditions, there has to be 12 
stronger coupling between ATP hydrolysis and E217βDG, when two molecules of E217βDG are bound.  13 
 14 
3.8. Dissociation	constants	for	the	first	and	second	cooperative	E217βDG	binding	sites	are	15 
similar	16 
The average Kd s (i.e. Kd2, Kd3 and Kd4, Kd5) of E217βDG cooperatively binding with ATP to site #1 and site #2 17 
determined in ATPase assays were 163 +/-38 µM and 128 +/- 34 µM, respectively (Table 2). The average Kd 18 
derived from transport assays in the presence of ATP and a single molecule of E217βDG (i.e. Kd2 and Kd3) was 19 
141 +/- 19 µM (Table 3). The average Kd value with ATP and two molecules of E217βDG (Kd4 and Kd5) derived 20 
from transport assays was slightly higher at 175 +/- 27 µM (Table 3). Kd values determined from transport 21 
experiments correlated well to Kd values derived from ATP hydrolysis experiments. The integrated mean Kd 22 
values of ATPase and transport experiments was calculated and depicted in Table 4. The average Kd s of 23 
E217βDG cooperatively binding with ATP to site #1 and site #2 were 155 +/-33 µM and 146 +/- 39 µM, 24 
respectively, showing no significant alteration of these dissociation constants. 25 
 26 
Experimental data points from Figures 2 and 3 as well as simulated data, obtained with the fitting parameters 27 
shown in Table 2 and 3, were plotted in Figure 6 to indicate the quality of simulation. 28 
 29 
4. Discussion 30 
In this study, we used the highly active and unique functional orthologue of the long ABCC transporters, 31 
DMRP, to shed light on the details of the working mechanism of ABCC proteins. Our analysis revealed the 32 
following. The NBDs of DMRP are non-equivalent, resembling those of ABCCs. There are two distinct binding 33 
sites for E217βDG. There is a strong non-reciprocal positive allosteric cooperativity in DMRP with both 34 
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E217βDGs being cooperative towards ATP. DMRP has a highly futile catalytic cycle in terms of E217βDG 1 
transport upon saturation of the first E217βDG binding site. DMRP exhibits reduced ATP hydrolysis and 2 
constant E217βDG transport rate with tighter coupling of ATPase to E217βDG transport upon saturation of the 3 
second E217βDG binding site. 4 
In DMRP, similarly to ABCC1, the N-terminal catalytic centre is degenerate, since the Walker B catalytic 5 
glutamate is replaced by an aspartate and the corresponding signature motif is also deviated from the consensus 6 
LSGGQ to LSVGQ. The C-terminal catalytic centre of DMRP, like that of ABCC1, completely agrees with the 7 
consensus sequence of ABC transporters. One of the hallmarks of ABCC transport mechanism is the 8 
asymmetric nature of the ATP hydrolysis occurring predominantly at the C-terminal NBD (13, 17). In our 9 
experiments lysine to methionine mutation of the C-terminal Walker A almost completely abolished enzyme 10 
activity while the analogous mutation of the N-terminal Walker A lysine perturbed ATP hydrolysis and 11 
E217βDG transport at lower extent. The double Walker A mutant DMRP was completely loss of function. 12 
Furthermore, we have previously shown that the substrate and inhibitor specificity of DMRP are typical for 13 
ABCC (48). This characterisation of DMRP was a prerequisite for its application as a model protein in in-depth 14 
analysis of the working mechanism of ABCC transporters.   15 
ABC transporters have an intrinsic ability to hydrolyse ATP even in the absence of their substrates. This 16 
intrinsic enzyme activity is often referred to as basal ATPase activity. Basal ATPase activity of the ABC 17 
transporters may vary significantly and it is characteristic of the transporter and of the measurement conditions. 18 
Transported substrates in principle stimulate the ATPase activity of ABC transporters allowing the coupling of 19 
ATP hydrolysis to substrate transport. However, transported substrates have been reported to paradoxically 20 
inhibit the ATPase activity of DMRP, a phenomenon that was explained by the existence of a hypothetical 21 
endogenous competitive modulator, either a substrate or an allosteric activator, in the Sf9 membranes (48). In 22 
line with this, we found that at high ATP saturation the established substrate E217βDG indeed reduced the ATP 23 
hydrolysis rate in a non-competitive manner. However, we found that at partial ATP saturation E217βDG 24 
significantly stimulated the ATPase activity of DMRP, at least in a certain concentration range. These results 25 
suggested that E217βDG and ATP have a complex interaction in the catalytic mechanism of DMRP. In order to 26 
elucidate this interaction, we determined ATPase and transport activity as a function of ATP in different 27 
E217βD concentrations. Conversely, we determined ATPase and transport activity as a function of E217βD in 28 
different ATP concentrations (Figure 2 and 3). This novel way to study enzymatic function enabled us to assess 29 
the interdependence of the interaction of ATP and E217βD on the catalytic cycle of DMRP. We found a 30 
dynamic concentration-dependent effect of E217βD on Vmax and KM for ATP. E217βD was able to shift the KM 31 
for ATP, however, ATP did not shift the KM for E217βD. We consider that our approach used here to 32 
characterize allosterically modulated enzyme activity is generally applicable. 33 
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Our data obtained with complementary approaches revealed the existence of two cooperative binding sites for 1 
E217βDG with similar dissociation constants. Interestingly, at limiting ATP concentration, the alternative 2 
scenario, assuming only the first E217βDG binding site being cooperative on ATP binding, gave almost as good 3 
fit as the best fitting model with two cooperative sites (Figure 5A). This phenomenon suggests that the binding 4 
of the first E217βDG is critical and sufficient for the cooperativity at low ATP saturation. At this ATP 5 
concentration, based on analogy to human ABCC transporters, only the non-canonical degenerate NBD is 6 
supposed to be saturated with ATP (17-19, 64). Therefore, it is plausible that the first E217βDG binding site is 7 
cooperative with the N-terminal NBD. In contrast, at excess ATP concentration the alternative model, with the 8 
first E217βDG binding being cooperative only, failed to give a good fit of the experimental data (Figure 5B). 9 
This implies that the saturation of the second E217βDG binding site is indispensable for cooperativity at high 10 
ATP saturation. Presumably, the second E217βDG binding site cooperates with the C-terminal canonical NBD, 11 
which is saturated only at excess ATP concentrations. Interestingly, saturation of the second E217βDG binding 12 
site, on a non-competitive manner, reduced rate constant for ATP hydrolysis by 90 percent, suggesting 13 
allostery-driven inhibition of ATP hydrolysis. 14 
Consequent to the two substrate binding sites, two distinct transport rates were distinguishable in our kinetic 15 
model. Surprisingly, in contrast to the one order of magnitude difference in the rate constants for ATP 16 
hydrolysis, the transport rate was not altered upon saturation of the second E217βDG binding site. At saturation 17 
of solely the first E217βDG binding site, DMRP exhibited almost entirely futile ATPase cycles, with 18 
approximately 180 ATP hydrolysed upon transport of a single E217βDG, supposing one molecule of ATP 19 
hydrolysed per cycle. In contrast, at excess E217βDG saturation, as the rate constant for ATP hydrolysis 20 
dropped one order of magnitude while E217βDG transport rate remained constant, coupling of ATP hydrolysis 21 
to transport was elevated by an order of magnitude. This gave a ratio of approximately 18 ATP hydrolysed per 22 
each E217βDG transported, supposing a single ATP is hydrolysed per catalytic cycle and one E217βDG 23 
molecule is transported per transport cycle. The allosterically driven boost of efficiency of E217βDG transport is 24 
achieved by hydrolysing less ATP with a maintained transport rate instead of transporting more substrate upon 25 
maintained level of ATP hydrolysis. 26 
The close homologue of DMRP, human ABCC2, also harbours two binding sites for E217βDG (44, 46). 27 
Transport of the first E217βDG molecule bound to the transport site is allosterically stimulated by binding of the 28 
second E217βDG to the allosteric site (46). However, for ABCC2 the mechanism of allosteric stimulation is not 29 
yet known. The phenomenon, that DMRP changes its coupling ratio at high extent depending on the saturation 30 
of an allosteric substrate binding site, is a remarkable finding. Taking the high level of sequential and functional 31 
homology of DMRP to human ABCC2 into account, our results raise the possibility that the reported allosteric 32 
stimulation of E217βDG transport in ABCC2 might be achieved by allostery-driven tighter coupling of ATP 33 
hydrolysis to transport.  34 
	 15	
The asymmetry in the effect of substrate binding to its distinct binding sites might be a characteristic feature of 1 
ABCC proteins. This could lead to an intimately orchestrated collaboration of substrates and non-equal catalytic 2 
centres and might also be relevant to co-transport of molecules, a phenomenon often found in the physiology of 3 
ABCCs. In conclusion, our work proposes allostery-driven boosting of coupling of ATP hydrolysis to transport 4 
as a relevant mechanism for ABCC transporters. 5 
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 44
Figure 1. Catalytic sites of DMRP are functionally non-equivalent  45 
A: Expression of wild-type and mutant DMRPs in insect cells. Immunoblot of membrane preparations of Sf9 46 
cells overexpressing wild type or N- or C-terminal single- or double- Walker A lysine mutant DMRPs or β-47 
galactosidase (β-gal). B:  Vanadate-sensitive basal ATPase activity of wild type and Walker A lysine 48 
	 19	
mutant DMRPs in Sf9 inside-out vesicles. Activities were measured in the presence of 3.33 mM Mg2+ATP 1 
using 30, 50, and 100-100 µg total membrane protein containing Sf9 membrane preparations overexpressing 2 
wild-type, K687M, K1349M and DKM DMRP, respectively. C: ATP-dependent E217βDG transport of wild 3 
type and Walker A lysine mutant DMRPs measured in the presence or absence of 4 mM Mg2+ATP at 100 4 
µM E217βDG concentration.  5 
Panels B and C depict the mean values of at least three independent experiments done in at least duplicates and 6 
error bars show the standard error of the estimate of mean value (S.E.M.). Activities were normalized to that of 7 
the wild type protein. 8 
  9 
Figure 2. Complex interaction of E217βDG and ATP in ATPase activity of wild type DMRP 10 
A: Basal ATPase activity as the function of Mg2+ATP; B: ATPase activity as a function of E217βDG 11 
concentration in the presence of 3.33 mM Mg2+ATP (closed diamonds, solid line) and in the presence of 12 
0.5mM Mg2+ATP (open diamonds, dashed line). C: ATPase activity in the absence or presence of various 13 
concentrations of E217βDG plotted as a function of Mg2+ATP concentration. Panels A, B and C depict mean 14 
values of at least three independent experiments done in at least duplicates. Error bars show the standard error 15 
of the estimate of mean value (S.E.M.). D: KM (open squares and dashed line, left Y axis) and Vmax (closed 16 
squares and solid line, right Y axis) for ATP in ATPase activity extracted from fits of panel C. Error bars show 17 
the standard deviation of mean value (S.D). 18 
 19 
Figure 3. Non-reciprocal cooperativity of E217βDG and ATP indicated in transport activity 20 
A: E217βDG transport as the function of Mg2+ATP concentration in the presence of 100 µM (closed diamonds, 21 
solid line) and 10µM (open diamonds, dashed line) E217βDG; B: KM (open squares and dashed line, left Y 22 
axis) and Tmax (closed squares and solid line, right Y axis) for ATP in transport activity as the function of 23 
E217βDG concentration extracted from fits of panel A.; C: E217βDG transport as the function of E217βDG 24 
concentration measured in the presence of 0.25, 0.75 and 3.33mM Mg2+ATP. D: KM (open squares and dashed 25 
line, left Y axis) and Tmax (closed squares and solid line, right Y axis) for E217βDG in transport activity as a 26 
function of Mg2+ATP concentration extracted from fits of panel C; Panels A and C depict mean values of at 27 
least three independent experiments done in at least duplicates. Error bars show the standard error of the 28 
estimate of mean value (S.E.M.).; Panels B and D depict extracted mean values, error bars show the standard 29 
deviation of mean value (S.D.). 30 
 31 
Figure 4. Kinetic model of wild type DMRP 32 
E refers to DMRP, Si to transported substrate (E217βDG) at the inward facing binding site, So to transported 33 
substrate at the outward facing binding site. When location of substrate is indispensable it is indicated by S?. 34 
Binding of E217βDG is indicated with dotted arrow, binding of ATP is indicated with solid arrow, ATP 35 
	 20	
hydrolysis is indicated with dashed arrow and transport of E217βDG is indicated with double arrow. Kinetic 1 
parameters are depicted in italics and refer to dissociation constants for ATP (Kd1, Kd3, Kd5), E217βDG (Kd2, 2 
Kd4), initial rate of ATP hydrolysis in the absence of E217βDG (Vmax basal) or in the presence of one or two 3 
molecules of E217βDG (Vmax1, Vmax2), respectively as well as initial rate of E217βDG transport in the presence of 4 
one or two molecules of E217βDG (T1, T2), respectively.  5 
 6 
Figure 5. Fit of experimental values and modelled scenarios for cooperativity 7 
A: Fit of the simulated ATPase activity of the 4 different scenarios (model#1-4, solid, dashed, dotted and 8 
dashed/dotted lines, respectively) (see Table 1) to the experimental values (open squares) from Figure 2B at 9 
limiting (0.5mM) ATP concentration.   10 
B: Fit of the simulated ATPase activity of model#1 and 2 (solid line and dashed line), respectively (see Table 1) 11 
to the experimental values (closed squares) from Figure 2B at excess (3.33mM) ATP concentration. 12 
 13 
Figure 6. Fit of the normalised experimental values and the corresponding simulated values derived from 14 
modelling in COPASI 15 
Symbols indicate experimental values while simulated data from Table 2 and 3 are depicted as lines. A: 16 
ATPase activity as a function of E217βDG concentration at limiting and excess ATP concentrations 17 
normalised to Vmax basal determined at excess ATP. B: ATPase activity as a function of ATP concentration 18 
with various E217βDG concentrations normalised to Vmax basal determined at excess ATP. C: E217βDG 19 
transport activity as a function of E217βDG concentration at different ATP concentrations normalised to 20 
Tmax of E217βDG transport determined at excess ATP concentration. D: E217βDG transport activity as a 21 
function of ATP concentration at different E217βDG concentrations normalised to Tmax of E217βDG 22 
transport determined at excess ATP concentration.     23 
 24 
Table 1. Cooperativity of E217βDG and ATP at limiting and excess ATP concentrations modelled in 25 
COPASI 26 
Kinetic parameters referring to ATPase activity were modelled using 4 different scenarios for limiting ATP 27 
concentration (0.5mM ATP): model#1: both ATP binding are cooperative (Kd2=Kd3;	Kd4=Kd5); model#2: first 28 
ATP binding is cooperative (Kd2=Kd3); model#3: second ATP binding is cooperative (Kd4=Kd5); model#4: none of 29 
the ATP bindings are cooperative. Kinetic parameters referring to ATPase activity were modelled using 2 30 
different scenarios for excess ATP concentration (3.3mM ATP): model#1: both ATP binding are cooperative 31 
(Kd2=Kd3;	Kd4=Kd5); model#2: first ATP binding is cooperative (Kd2=Kd3); To show quality of the fits the R and 32 
Chi2 values are also provided. 33 
 34 
Table 2. Kinetic parameters of ATP hydrolysis determined by modelling in COPASI 35 
	 21	
Kinetic parameters for ATP hydrolysis of wild type DMRP were calculated using COPASI software, based on 1 
the kinetic model#1 represented in Figure 4. The R and Chi2 values of the fits are also provided. 2 
 3 
Table 3. Kinetic parameters of E217βDG transport determined by modelling in COPASI 4 
Kinetic parameters for E217βDG transport of wild type DMRP were calculated using COPASI software, based 5 
on the kinetic model#1 represented in Figure 4. The R and Chi2 values of the fits are also provided. 6 
  7 
Table 4. Integrated kinetic parameters of ATPase activity and E217βDG transport 8 
The mean values of the kinetic parameters of Table 2 and 3 were calculated and presented as integrated activity. 9 
R and Chi2 values of the fits are also provided. 10 
 11 
 12 








